Patents by Inventor Fengyun Pei

Fengyun Pei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition for treating locally advanced mismatch repair-proficient/microsatellite stable (PMMR/MSS) colorectal cancer (CRC) and use thereof
    Patent number: 12053472
    Abstract: Disclosed are a pharmaceutical composition for treating locally advanced mismatch repair-proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) and use thereof. The pharmaceutical composition of the present disclosure includes mFOLFOX6, bevacizumab, and a PD-1 inhibitor. Experimental results show that, when the pharmaceutical composition is used to treat 18 locally advanced (T4N×MO) MSS CRC cases, major pathological remission (tumor regression exceeds 90%) is achieved in 14 cases and pathological complete remission (no residual tumor cells) is achieved in 10 cases; tumor marker levels are all lowered to normal levels; there is no fatal serious adverse event (SAE); and the pharmaceutical composition has prominent safety and efficacy.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: August 6, 2024
    Assignee: The Sixth Affiliated Hospital, Sun Yat-sen University
    Inventors: Jun Huang, Meijin Huang, Yanhong Deng, Fengyun Pei, Jianping Wang
  • PHARMACEUTICAL COMPOSITION FOR TREATING LOCALLY ADVANCED MISMATCH REPAIR-PROFICIENT/MICROSATELLITE STABLE (PMMR/MSS) COLORECTAL CANCER (CRC) AND USE THEREOF
    Publication number: 20230285395
    Abstract: Disclosed are a pharmaceutical composition for treating locally advanced mismatch repair-proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) and use thereof. The pharmaceutical composition of the present disclosure includes mFOLFOX6, bevacizumab, and a PD-1 inhibitor. Experimental results show that, when the pharmaceutical composition is used to treat 18 locally advanced (T4NxM0) MSS CRC cases, major pathological remission (tumor regression exceeds 90%) is achieved in 14 cases and pathological complete remission (no residual tumor cells) is achieved in 10 cases; tumor marker levels are all lowered to normal levels; there is no fatal serious adverse event (SAE); and the pharmaceutical composition has prominent safety and efficacy.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 14, 2023
    Inventors: Jun Huang, Meijin Huang, Yanhong Deng, Fengyun Pei, Jianping Wang